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Abstract
Toscana virus (TOSV) is an emerging virus, circulating in theMediterranean area, that is responsible for aseptic meningitis, meningoencephalitis,
and encephalitis. The development of a vaccine that could provide complete protection from TOSV infection is needed. In this study we investigated
the capacity of TOSV structural proteins, nucleocapsid protein N and the two Gc and Gn glycoproteins, produced as recombinant proteins, in an
animal model. In particular, we investigated their role in inducing specific and protective immune responses against virus infection. Mice were
immunized intraperitoneally using TOSV antigens singly or in combination. The results show that only the N-Gc combination was able to protect
100% of animals from a lethal challenge with a neurovirulent strain of TOSV. This potential vaccine induces high serum antibody titres with
neutralizing activity and it is safe for animals. Moreover, immunization induces a virus specific cell-mediated immune response, in particular a CD8+
T cell response associated with a marked expression of interferon gamma. These results indicate that the N+Gc viral antigen combination could be
useful for future development of a vaccine controlling the spread of this emerging virus that could pose a new threat for humans.
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Toscana virus is an enveloped negative-strand RNA virus of
the Bunyaviridae family, Phlebovirus genus (Bishop, 1990;
Elliot et al., 1991). Rift Valley virus and sandfly fever viruses are
themost important viruses of this genus (Gonzales-Scarano et al.,
1982; Gonzales-Scarano and Nathanson, 1990; Nicoletti et al.,
1991; Tesh, 1988;Meegan andBailey, 1988). Some sandfly fever
viruses, such as Toscana virus (TOSV), are currently circulating
in Europe. TOSV is responsible for aseptic meningitis,
meningoencephalitis, or encephalitis associated with fever,
myalgia, severe frontal headache, vomiting, ocular pain and
nuccal rigidity (Braito et al., 1998b; Dionisio et al., 2001;⁎ Corresponding author. Department of Molecular Biology, Microbiology
Section, University of Siena, Policlinico Le Scotte, V.le Bracci, 1, 53100 Siena,
Italy. Fax: +39 0577 233870.
E-mail address: cusi@unisi.it (M.G. Cusi).
0042-6822/$ - see front matter © 2008 Elsevier Inc. All rights reserved.
doi:10.1016/j.virol.2008.02.006Nicoletti et al., 1991; Valassina et al., 1998a; Valassina et al.,
2000). Asymptomatic infections and infections without CNS
involvement of this virus have also been described (Braito et al.,
1997). Toscana virus is endemic in the Mediterranean countries
where its vector, phlebotomus, is present. TOSV infection has
been reported in residents of, and visitors returning from,
endemic areas, mainly Portugal, Spain, Cyprus and central Italy
(Calisher et al., 1987; Dobler et al., 1997; Ehrnst et al., 1985;
Eitrem et al., 1991a,b; Eitrem et al., 1990; Endris and Perkins,
1987; Schwarz et al., 1993; Schwarz and Jager, 1995; Tesh et al.,
1976). This neuropathogenic infection is more frequent during
the summer, depending on the life cycle of the insect vector.
Epidemiologic studies have shown that TOSV is the most
important etiologic agent of meningitis and meningoencephalitis
in endemic areas (Braito et al., 1998a; Echevarria et al., 2003;
Valassina et al., 1998a,b) during the summer, causing an increase
in hospitalization rates and having an important impact on human
health. Currently, there is no effective treatment for the infection-
Fig. 1. Immunofluorescence localization of TOSV Gn or Gc using a mouse polyclonal anti-Gn or anti-Gc serum on Sf9 insect cells mock infected (A) or infected with
Bac-Gn (B) or Bac-Gc (C) recombinant baculovirus. Fluorescence is localized in the cytoplasm (magnification ×100).
Table 1
Mice immunization chart
Groups of mice Antigens injected (100 μl) for immunization
1 Inactivated TOSV (105 PFU/ml)
2 Lysate of 1×106 Sf9 cells infected by Bac-Gn
3 Lysate of 1×106 Sf9 cells infected by Bac-Gc
4 Lysate of 1×106 Sf9 cells infected by Bac-Gn+100 μg
of rN protein
5 Lysate of 1×106 Sf9 cells infected by Bac-Gc+100 μg
of rN protein
6 Lysate of 1×106 Sf9 cells infected by Bac-Gn+lysate of
1×106 Sf9 cells infected by Bac-Gc+100 μg of rN protein
7 Lysate of 1×106 Sf9 cells infected by Bac-Gn+lysate of
1×106 Sf9 cells infected by Bac-Gc
8 100 μg of rN protein
9 Lysate of 1×106 Sf9 cells infected by baculovirus
10 Lysate of 1×106 Sf9 cells
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effective and safe vaccine. Toscana virus contains a segmented
negative-strand RNA genome consisting of three noncovalently
closed, circular RNA segments, (Large,Medium and Small). The
different segments code respectively for the large protein (L)
(Accardi et al., 1993), the envelope glycoproteins (Gn and Gc)
(Di Bonito et al., 1997; Gro et al., 1997), the nucleocapsid protein
(N) and the non structural protein (NS) (Giorgi et al., 1991). The
anti-N antibodies have been shown to have a partial neutralizing
activity (Cusi et al., 2001) while in other viruses of this family,
Rift Valley fever virus, La Crosse virus and Hantaan virus, the
neutralizing activity is a property of the anti Gn-Gc antibodies
(Saluzzo et al., 1989a,b; Gonzalez-Scarano et al., 1982; Grady
andKinch, 1985; Arikawa et al., 1989). In human infection, theN
protein is immunodominant while the anti-glycoprotein response
is practically absent (Cusi et al., 2002; Di Bonito et al., 2002).
This antigenic immunodominance has suggested an important
role of N in human infection. In fact, a strong cytotoxic T cell
response specific for N has been found in patients affected by
virus-associated meningitis (Cusi et al., 2002). The mechanisms
of protection against TOSV natural infection are not known,
however it could be supposed that a virus-neutralizing antibody
response is not sufficient but that a T cell helper and effector
mechanismsmight also play a role.We have recently developed a
mouse model for studying TOSV pathogenesis (Cusi et al.,
2005). Adult Balb/c mice have been made susceptible to TOSV
by intracerebral infection (ic.) with a neurovirulent adapted strain
of the virus (Cusi et al., 2005) causing death. The aim of this
study was to evaluate in vivo, the ability of the different TOSV
antigens, alone or in combination, to protect the animals against
virus challenge. Safety, immunogenicity and efficacy of the
possible vaccine products are discussed.
Results
Immunization of mice with TOSV proteins
N protein was produced in E. coli and purified according to
the previously described method (Valassina et al., 1998b). This
procedure produced a large amount of purified N protein for
immunizations (Soldateschi et al., 1999; Valassina et al., 1998b).
The ectodomains of Gn and Gc proteins were expressed in Sf9
cells infected by recombinant baculovirus (Di Bonito et al.,2002). The expression of these proteins reached the maximum
five days after infection, when about 70% of the cells were
positive for the antigen, as revealed by IF performed by using
specific sera. Gc and Gn were purified from the culture
supernatant where they were secreted lacking the transmem-
brane signal. Unfortunately, the amount of proteins recovered
after HPLC purification was not sufficient for animal immuniza-
tion. We then immunized the mice with the specific protein-
containing cell lysates (about 60 μg of protein/dose). Fig. 1
shows an immunofluorescence picture of protein localized
inside the cytoplasm, possibly in the secretory vesicles.
In order to establish the immunogenicity and the protective
immune response of the TOSV structural proteins, groups of
mice were immunized with the single antigens or their different
combinations using the proper dose of antigen capable of in-
ducing a specific immune response as determined in preliminary
experiments (data not shown). Ten groups of mice were
immunized using the purified N protein and Sf9 cell infected
lysates containing the Gn or Gc proteins, as reported in Table 1.
Protection of immunized mice
In the first set of in vivo experiments mice immunized with a
multiple combination of antigens (Table 1), and with inactivated
virus, were compared. Twelve days after the last immunization,
Fig. 2. Animal protection assay: adult Balb/c mice were previously ip. inoculated with multiple antigens and their survival observed at the 7th (□) and 20th (■) day
after ic. challenge with 10 LD100 of TOSV (1812V) strain.
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ulation and observed for two months. LD100 was used instead of
LD50 to better demonstrate the eventual complete protection of
animals against virus infection.The results, in terms of the
percentage of surviving mice, show (Fig. 2) that all the animals
immunized with inactivated TOSV survived after the challenge,
while only a percentage of those immunized with N+Gn+Gc
(40%), N+Gc (40%) and N alone (20%) survived. The differ-
ence in survival was significant (Fisher exact test; p=0.023).
Mice inoculated with inactivated TOSV displayed no clinical
signs. The remaining surviving mice displayed mild signs of
lethargy and ruffled fur for four–five days after challenge and
then recovered complete vitality. These preliminary data seem
to indicate that, among the various combinations of antigens, N
and Gc are the two antigens necessary for inducing partial
protection.The addition of Gn to the N+Gc combination does
not seem to augment protection and Gn in association with N
seems to induce less protection after challenge. ImmunizationFig. 3. Animal protection assay: adult Balb/c mice previously ip. inoculated with PB
protein (—□—) or lysate of Sf9 cell infected by Bac-Gc+rN protein (—○—) werwith each protein alone was not able to protect mice, except for
the N protein which, however, conferred a lower protection
level than the N+Gc combination.
On the basis of these results, a second set of in vivo exper-
iments was carried out using the N and Gc proteins alone or in
combination. Considering that TOSV was administered to mice
ic. and not by the natural route of infection, a dose of 10 LD100
of virus injected directly in the brain could be too high a dose to
be blocked by the immune system, as usually occurs in vivo,
thus we reduced the dose of virus for challenge to 1 LD100, an
amount that is still able to kill mice.
The results confirmed that N+Gc is the combination of
antigens which confers complete protection (100%) to mice ic.
challenged with TOSV (Fig. 3). A low level of protection was
also observed in mice immunized with the N protein alone,
indicating that this antigen is able to induce a strong CTL
response (Cusi et al., 2002) which, together with a low level of
neutralizing antibodies, partially protects the animals (Fig. 4).S (—△—), UV inactivate TOSV (—■—) and protective antigens, such as rN
e ic. challenged with 1 LD100 of TOSV (1812V) strain.
Fig. 4. Cytotoxic activity from splenocytes of mice immunized with lysate of
Sf9 cells infected by Bac-Gc+rN protein (—◆—), rN protein (—□—),
inactivated TOSV (—▲—) and PBS (——●——). Target cells, P815 cells
infected with TOSV (A) or uninfected P815 (B) cells were mixed with effector
cells for 6 h at 37 °C at 25:1, 12.5:1, 6.25:1, 1:1 E:T ratio. A 6-h 51Cr release
assay was performed; results are presented as the % of specific lysis. The data
shown are mean values from five mice of each group of immunized mice±SD.
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survived. All the surviving mice were sacrificed two months
after challenge and their organs, including the brain, lungs and
liver, were taken for pathological analyses. No relevant
pathological data was recorded in any of the mice.
In order to evaluate whether the specific antibodies could
have a role in protection against viral infection, the animal sera
with a high titre of specific antibodies and with neutralizing
activity were pooled and transferred to naive mice before lethal
challenge with TOSV. Immune serum recipients showed signs
of illness and all died within ten days after virus challenge,Table 2
Evaluation of humoral response of immunized mice by different assays
Immunized mice ELISA Immunoblot Neutralization
Group A (N+Gc) 26972±921 Presence of anti-N,
Gc antibodies
36.4±5.6
Group B (N) 26812±448 Presence of anti-N
antibodies
4±1.1
Group C (TOSV) 28160±1142 Presence of anti-N,
Gn, Gc antibodies
128±47.2
Group D (PBS) b100 Absence of anti-TOSV
antibodies
b4
Values of antibody titre are given as GMT±SD.indicating that the protection against infection was not com-
pletely mediated by circulating antibodies.
Humoral response to TOSV antigens elicited by immunization
The presence of specific anti-TOSV antibodies was always
confirmed in immunized mice before virus challenge by ELISA.
However the antibody response to ip. immunization was
evaluated in mice of groups A–D by different serological tests.
All mouse sera reacted with the recombinant N protein, used as
antigen, with Ab titre up to 1/51,200, in the ELISA test. The
samples were also tested by immunoblotting on lysates of Sf9
cells infected with Bac-Gc or Bac-Gn recombinant baculovirus,
uninfected Sf9 cells and purified rN protein. All mice, except
those of the control group (group D), reacted with the N protein,
while only those of groups A and C (mice immunized with Bac-
Gc cell lysate+N protein or UV inactivated TOSV, respectively)
revealed the presence of specific anti-Gc antibodies. Samples
were also analysed in a neutralization assay. Only sera frommice
immunized with Gc+N proteins showed a good neutralizing
activity (GMT 36.4±5.6). Mice immunized with the N protein
showed a significantly lower neutralizing titre (GMT 4±1.1)
(P=0.03). A very high neutralizing titre (GMT 128±47.2) was
observed in sera from mice immunized with inactivated TOSV,
while control mice did not develop any specific anti-TOSV
antibodies (Table 2).
Cell-mediated immune response in immunized mice
Production of interferon gamma was revealed in the lym-
phocytes of all immunizedmice groups, as shown in Table 3.Mice
immunized with N or N+Gc showed a similar level of IFN-γ, not
significantly different from that observed in mice immunized with
the whole virus (P=0.062). However, a low amount of IL-5 was
found only in mice immunized with inactivated TOSV.
These results indicate that both N andN+Gc antigens are able
to induce a Th1 response, characterized by the production of IFN-
γ, favouring cell-mediated immune responses and the activation
of CD8+ cytotoxic T cells (CTLs). We also investigated whether
immunization with N or N+Gc would elicit a CTL response. A
marked specific CTL activity was observed in all groups of mice,
except in the control group. Among the different groups of
immunizedmice, the highest cytolytic activity was found in those
immunized with inactivated TOSV (40.9%±6.4 specific release)
(P=0.009). On the contrary, the difference in terms of cytolytic
activity between the groups immunized with N or N+Gc
(P=0.18) was not significant. No cytolysis was observed against
uninfected P815 cells (Fig. 4).Table 3
Antigen-specific cytokine production from splenic cells of immunized mice
Immunized mice IFN-γ (ng/ml) IL-5 (pg/ml)
Group A (N+GC) 2.70±1.28 ND
Group B (N) 1.64±0.49 ND
Group C (TOSV) 4.16±0.78 9.3±3.24
Group A (PBS) ND ND
ND: not detectable; Values are given as the mean±SD.
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Emerging and re-emerging viral infections have been an
important public health problem in recent years. These are issues
of serious concern, along with the spread of the emergent
neurotropic Toscana virus in Mediterranean area (Schwarz et al.,
1993; Schwarz and Jager, 1995; Portolani et al., 2002; Valassina
et al., 2003). Preventive strategies for the control of these
infections, particularly vaccine strategies, must be considered in
view of the evolution of infective agents, globalization and
habitat modification. Thus prevention, by the use of old and new
vaccines, is fundamental to greatly reduce the emergence of
severe viral infections and there is a continual effort to design
safer and more efficacious vaccines. We have investigated
immune responses induced by TOSV antigens, including
antibody neutralizing activity and cellular immune response. A
potential vaccine was evaluated in mice for its protective ability
against virulent TOSV challenge. In mouse trials, the recombi-
nant N protein was able to confer a partial protection against
TOSV (about 60% survival); complete protection was obtained
only in mice immunized with the combination of N+Gc
proteins, suggesting that this formula could be a good candidate
for the development of a vaccine. The ability of N to confer
protection to mice at a high percentage is not surprising because
it is able to induce a strong cell-mediated immune response and
antibodies with a partial neutralizing activity. This result is
similar to that obtained by Wallace et al. (2006) who, sur-
prisingly, obtained a protection of 60% in mice immunized with
Rift Valley fever virus N protein after virus challenge.
The prominent result of this study is, however, the recognition
that immunization with the N+Gc protein combination is able to
induce complete protection against TOSV in mice. Immunolo-
gical analysis shows that this immunization induces a marked
specific CD8+ mediated cytotoxic activity and a good neutraliz-
ing activity in mice. Passive transfer of specific anti-TOSV
immunoglobulins was unsuccessful in protecting mice, indicat-
ing that an active cell-mediated immune response is essential to
confer protection. The in vivomodel used in this study, based on
the ic. viral challenge, is not the most appropriate method for
evaluating the protection level of circulating specific antibodies,
but it is the only animal model available at the moment. It is still,
however, a validmodel for the first step in testing the efficacy of a
vaccine. Moreover, the high expression of IFN-γ in mice
immunized with N alone or N+Gc indicates that N is mostly
responsible for T lymphocytes activation. Animals that survived
the TOSV challenge did not show any clinical signs or suffering
and their vitality lasted until they were sacrificed two months
later. These results could clarify the protective and pathogenic
mechanisms that can be manipulated in order to prevent the
disease. In the development of a vaccine it is very useful to have
an immunological correlate of protection, which can be used to
evaluate different vaccine formulations. In this sudy, it appears
that the inactivated virus and the recombinant proteins are able to
prevent the disease providing some new elements useful for the
development of new generation of safer and more efficacious
sub-unit vaccines. Since vaccinology is entering a new era in
which knowledge about the pathogen and the determination ofimmunodominant proteins are being integrated with an under-
standing of the host immune response, this study provides insight
for laying the basis and developing an efficacious vaccine based
on recombinant proteins to fight an emerging virus that could
pose a new threat to humans.
Materials and methods
TOSV virus and cells
A TOSV strain (1812) isolated from the cerebrospinal fluid
(CFS) of a patient with meningitis was used for all infections.
The virus was passaged twice in Vero cells (ATCCCCL-81), and
once in McCoy cells (ATCC CRL-1696), then titrated. The virus
(103 PFU), was then inoculated into the brains of newborn mice
(Balb/c, Charles River, Milan, Italy). After one week, the mice
were sacrificed and the brain homogenates were inoculated
intracerebrally (ic.) into newborn mice. The infected brains were
collected, homogenized on ice by a dounce in Minimum
Essential Medium (MEM) (Life Technologies, Milan, Italy)
supplemented with 2% fetal bovine serum (Life Technologies)
and clarified by centrifugation at 4 °C for 20 min at 2000 ×g.
This virus (103 PFU) was used to ic. infect adult mice which died
after 7 days. The brain homogenate was used to infect Vero cells
to produce a virus stock which had a titre of 1.2×106 PFU/ml.
This virus, called TOSV strain 1812 V (Cusi et al., 2005), was
used for the challenge of immunized adult mice.
Detection of expressed TOSV Gn and Gc proteins
Spodoptera frugiperda cells (Sf9) were propagated in SF-900
II medium (GIBCO InVitrogen, Milan, ITALY) containing
streptomycin (100 mg/ml; Life Technologies), and penicillin
(100 UI/ml; Life Technologies). Cells were infected with each
recombinant baculovirus, Bac-Gn and Bac-Gc, expressing the
ectodomains of Gn and Gc of TOSVat a multiplicity of infection
(MOI) of 0.1 plaque-forming units (PFU/cell), as previously
described (Di Bonito et al., 2002). Cells were collected five days
post-infection and tested for protein expression using a mouse
polyclonal anti-Gn or anti-Gc serum, by immunofluorescence (IF)
(Di Bonito et al., 1997). When more than 70% were positive for
TOSV, cells were collected and frozen at −80 °C. 106 infected
cells produced about 60μg of recombinant protein, approximately
estimated by SDS-PAGE and immunoblot (data not shown). After
2 cycles of freeze-thawing, cells were suspended in a physiolo-
gical buffer (NaCl 0.9%) and used for the immunization of mice.
TOSV N protein production
Recombinant TOSV N protein was expressed in E. coli and
purified by affinity chromatography, as previously described
(Soldateschi et al., 1999; Valassina et al., 1998b).
Immunization and viral challenge of mice
Four week-old female BALB/c mice (Charles River, Milan,
Italy) were used in the immunization experiments. Each
526 G. Gori Savellini et al. / Virology 375 (2008) 521–528experiment was repeated three times to assess the reproducibility
of results. Groups of 5 mice were immunized with four
consecutive intra-peritoneal (ip) injections of different combina-
tions of viral antigens, administered three weeks apart as
described in Table 1. Twelve days after the last immunization,
the mice were ic. challenged with 10 LD100 (50 PFU) of TOSV
(1812V) and monitored for clinical symptoms; survivors were
observed for 2 months. A second set of experiments was carried
out, in light of the previous results, on only four groups of mice
(n=10 mice). The animals were ip. immunized with: (group A)
100 μl of a cell lysate expressing Gc protein together with 100 μg
of rN protein; (group B) 100 μg of rN protein; (group C) 100 μl
of UV inactivated TOSV (105 PFU/ml) and (group D) 100 μl of
phosphate buffered saline (PBS). All antigens were injected with
an equal volume of complete or incomplete Freund's adjuvant
(Sigma, Milan, Italy). All mice were immunized three times at
three week intervals and were ic. challenged with 1 LD100 of
TOSV (1812V strain) twelve days after the last immunization.
The surviving animals were observed for two months and then
sacrificed. This experiment was repeated twice in order to
confirm the results. The last experiment was performed in
duplicate: half of the animals were subjected to virus challenge
and the other half were analysed for immunological responses.
TOSV antibody titers were determined by using an ELISA test
(Soldateschi et al., 1999; Valassina et al., 1998b), an immunoblot
assay and a neutralization assay. Blood and spleen were drawn
from immunized mice for these examinations. All animal
experiments were carried out according to the UK Coordinating
Committee for Cancer Research Guidelines (Workman et al.,
1998). Survival curves were constructed using the Kaplan and
Meier method (Kaplan and Meier, 1958). Comparisons within
groups were carried out by two-tailed analysis.
Passive transfer of anti-TOSV IgG in mice
The sera of TOSV infected mice with IgG titres ranging from
25,600 to 51,200 by ELISA were collected, pooled and γ
irradiated (5×106 rads). IgG were then purified with a protein
G-sepharose affinity column (Sigma Aldrich), dialyzed against
PBS (pH 7.2) and filter sterilized for injection. For serum
transfer experiments, mice were given of 500 μl of purified anti-
TOSV IgG, or normal mouse serum ip. one day before ic.
challenge with TOSV.
Determination of humoral response. ELISA
Anti-TOSV IgG were evaluated by using an ELISA test
(DIESSE S.p.A, Siena, Italy) as suggested by the manufacturer.
Neutralization assay
Virus neutralization was carried out on Vero cells in a 96 well
microplate. Briefly, serial two-fold dilutions (50 μl) of
immunized mice serum were added to an equal volume of
TOSV containing 100 TCID50 and incubated for 90 min at
37 °C. Fifty μl of cells (106/ml) were suspended in MEM
(InVitrogen, Milan, Italy) with 5% FCS and added to each well.Five days after incubation at 37 °C, the cultures were examined
microscopically for the presence of cytophatic effect. The 50%
end point titre of the serum neutralizing dose was calculated
using the Reed and Muench method (Nicoletti et al., 1991).
Immunoblot
Sf9 cells in 35-mm plates (1.5×106 cells/well) were infected
with Bac-Gn and Bac-Gc recombinant baculoviruses at a
multiplicity of infection (m.o.i.) of 0.1. Infected and uninfected
cells were lysed in 100 μl of sodium dodecyl sulfate (SDS)-
loading buffer (50 mM Tris–HCl, pH 6.8, 5% β-mercaptoetha-
nol, 3% SDS, 50% glycerol, 0.5% bromophenol blue). Cell
extracts (200 μl) were boiled for 5 min and processed by
polyacrylamide gel electrophoresis (SDS-PAGE) and western
blotting, using the sera of immunized mice (groups A–D), or
mouse polyclonal serum specific to Gn, Gc or N proteins (Di
Bonito et al., 1997). The filter bound immunoglobulins were
detected by peroxidase-conjugated goat anti-mouse IgG (Sigma
dil: 1:1000) by colorimetric substrate.
Cytokine assay
Splenocytes were drawn from immunized mice and
lymphocytes were collected using Fycoll–Hypaque (Pharma-
cia) gradient. Unfractionated cells (1×106) were cultured in
1 ml of complete RPMI 1640 plus 10% FCS with 30 μg/ml of
purified inactivated TOSV or concanavalin (ConA) (Sigma)
(5 μg/ml) in 24 well flat-bottomed plates. Only the cell
suspension was added to control wells. After 48 h in culture,
cell-free supernatants were harvested for IFN- γ and IL-5
analysis and stored at −80 °C. Briefly, microtiter plates were
coated overnight at 4 °C with 100 μl of anti-cytokine capture
mAb (Pharmingen, Milan, Italy) at 1 μg/ml. The plates were
then washed twice with PBS-Tween and blocked with 100 μl of
10% FCS in PBS per well for 2 h at room temperature. The
plates were then washed twice and incubated with duplicates of
serially diluted samples and standards (Sigma) overnight at
4 °C. One hundred μl of the biotinylated anti-cytokines
(Pharmingen) mAb at 1 μg/ml was then added to each well
and the mixture was incubated at room temperature for 1 h.
After three washes, 100 μl of streptavidin-peroxidase (1/1000)
(Sigma) was added to the plates and the mixture was incubated
at room temperature for 30 min. Following multiple final
washings, the color was developed with TMB (Sigma) and
stopped with 100 μl of 0.5 N H2SO4, and absorbance at 405 nm
was measured with an ELISA plate reader (BIORAD, Milan,
Italy). The concentration of cytokines in the samples was
determined according to the standard curve.
Determination of T cytotoxic cell response
Splenocytes from mice in groups A–D were also tested for
cytotoxic activity against TOSV infected cells. Uninfected P815
cells and P815 cells infected with TOSV at a m.o.i. of 1 for
5 days were collected and used as target cells in CTL cytotoxic
assays. The percentage of infected cells was determined by IF
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S.p.A., Siena, Italy). Target cells were labelled with 51Cr
(chromic chloride, 37 Mbq, 1 mCi, Amersham, UK) in a
volume of 0.25 μl of RPMI-1640 for 30 min at room
temperature (5000–10,000 cpm/well). After two washings
with PBS without Ca++ and Mg++, target cells (1×104) were
seeded in 96 U-bottom multiwell plates in a volume of 100 μl.
Lymphocytes in a volume of 100 μl were added to the wells at
different Effector/Target ratios (25, 12.5, 6.25:1 and 1:1). The
plates were then incubated for 4 h at 37 °C in a humidified
atmosphere containing 5% CO2. One hundred μl of supernatant
was harvested for gamma counting. Experiments were carried
out in triplicate. Specific lysis was calculated using the
following formula:
Experimental point ðcpmÞ spontaneous release ðcpmÞ
Total release spontaneous release ðcpmÞ  100
Spontaneous release was determined by counting super-
natants in target cells not exposed to lymphocytes, and total
release was determined by treating the target with 2.5% Tryton
x-100.Statistical analysis
The statistical analysis of differences between means was
performed using Stat View statistical software (Abacus
Concepts, Berkeley, CA, USA). Differences among means
were determined by the Mann–Whitney rank sum test. Anti-
body titres are presented as geometric mean±standard devia-
tion. Pb0.05 was considered significant.
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